Ignite Creation Date:
2024-05-06 @ 3:20 PM
Last Modification Date:
2024-10-26 @ 1:47 PM
Study NCT ID:
NCT04592991
Status:
TERMINATED
Last Update Posted:
2022-04-15
First Post:
2020-10-05
Brief Title:
CCR2 AAA Pilot Study
Sponsor:
Washington University School of Medicine
Organization:
Washington University School of Medicine
Study Overview
Official Title:
Targeted Molecular Probe for Abdominal Aortic Aneurysm Imaging and Therapy
Status:
TERMINATED
Status Verified Date:
2022-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
We were only able to enroll 1 subject so we had no way to compare a control or other study groups and develop any kind of results This study is essentially the same study as NCT04586452 which we would like to place focus and effort on that study
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this research study is to look at whether an investigational imaging agent 64Cu-DOTA-ECL1i used during Positron Emission Tomography PET Computed Tomography CT scanning can help to identify conditions that place patients at an increased risk for AAA rupture The study is also looking more closely at cellular molecular and inflammatory properties of the aortic wall Having the ability to identify markers that predict AAA progressionexpansion and risk for rupture could allow the physician to manage patients in a more individualized personal way
Detailed Description:
Abdominal aortic aneurysm AAA is a life-threatening degenerative vascular disease characterized by transmural aortic macrophage infiltration elastin degradation and reduction of smooth muscle cell content AAAs occurs later in life and are especially prevalent in men over the age of 65 Patients typically remain asymptomatic until rupture which is associated with high mortality Currently surgical repair is the only approach for AAA treatment and there is no pharmacological intervention Clinically ultrasound and computed tomography measurement of aneurysm diameter represents the mainstay of management and the principal determinant of timing for elective surgical repair However this anatomy-based approach fails to provide useful information about the cellular and molecular processes associated with aneurysm expansion and rupture Therefore developing translatable molecular biomarkers specifically expressed by aneurysms is necessary to determine associated status and progression capture the risk of rupture and deliver personalized treatment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None